TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.

Microsoft's CEO, Satya Nadella, has announced BioEmu-1, a new AI system designed to accelerate drug discovery by decoding ...

Satya Nadella has unveiled BioEmu, Microsoft's new AI initiative aimed at accelerating drug discovery processes.

Microsoft's BioEmu, an AI-driven model, decodes protein motion to enhance drug discovery, offering rapid insights into ...

Centella AI streamlines drug discovery using AI-powered platforms, reducing R&D time and cost with real-world scientific validation ...

Understanding protein motion is essential to understanding biology and advancing drug discovery,” said Nadella, in a post on ...

The start-up, which aims to raise tens of millions of US dollars in an angel funding round, hopes to compete globally, ...

Microsoft’s new AI system BioEmu will help decode protein motion and help in faster discovery of drugs, said CEO Satya ...

A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to develop its signature cancer drug. IGI Therapeutics SA, a subsidiary of the ...

UTEC is one of Japan’s largest science and technology-focused VCs, with a portfolio spanning more than 150 companies either ...

Microsoft's CEO, Satya Nadella, has introduced BioEmu-1, a new AI system designed to accelerate drug discovery by decoding protein motion.

Hiding in Plain Sight Quantum computing has surged from theoretical curiosity to a transformative frontier, promising to ...